Reviva Pharmaceuticals (NASDAQ:RVPH) Posts Quarterly Earnings Results, Beats Estimates By $0.29 EPS

Reviva Pharmaceuticals (NASDAQ:RVPH) announced its quarterly earnings results on Wednesday. The company reported ($0.46) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.29, FiscalAI reports.

Reviva Pharmaceuticals Trading Down 55.7%

Shares of NASDAQ:RVPH opened at $0.35 on Thursday. Reviva Pharmaceuticals has a 12-month low of $0.26 and a 12-month high of $23.20. The company has a market capitalization of $4.51 million, a PE ratio of -0.04 and a beta of 0.75. The business has a 50 day moving average of $1.36 and a two-hundred day moving average of $6.01.

Wall Street Analysts Forecast Growth

RVPH has been the topic of several analyst reports. Maxim Group lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 8th. D. Boral Capital lowered Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, March 5th. Wall Street Zen raised Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, April 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $66.67.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new stake in shares of Reviva Pharmaceuticals in the second quarter valued at approximately $31,000. Lido Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the third quarter valued at approximately $37,000. NewEdge Advisors LLC purchased a new stake in shares of Reviva Pharmaceuticals in the first quarter valued at approximately $58,000. State Street Corp increased its position in shares of Reviva Pharmaceuticals by 202.4% in the fourth quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after buying an additional 256,500 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals by 6.9% in the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after buying an additional 29,063 shares in the last quarter. 63.18% of the stock is owned by institutional investors and hedge funds.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.